Skip to main content
editorial
. 2017 Aug 29;6(4):253–263. doi: 10.1159/000479573

Table 2.

Results of the REFLECT trial

Lenvatinib (95% CI) (n = 478) Sorafenib (95% CI) (n = 476) Hazard ratio (95% CI)
Median OS, months 13.6 (12.1–14.9) 12.3 (10.4–13.9) 0.92 (0.79–1.06)
Median PFS, months* 7.4 (6.9–8.8) 3.7 (3.6–4.6) 0.66 (0.57–0.77)
Median TTP, months* 8.9 (7.4–9.2) 3.7 (3.6–5.4) 0.63 (0.53–0.73)
ORR, n (%)* 115 (24) 44 (9) -

OS, overall survival; PFS, progression-free survival; TTP, time to progression; ORR, overall response rate.

*

p < 0.0001.